



## **Circular No. (5) 2023**

**Date: 28 February 2023**

**To: All Agents/Distributors (Importers) in the Kingdom of Bahrain**

**Subject: GS1 Participation with Use of the NHRA-MVC Traceability Hub for Pharmaceutical Product Traceability**

As per Resolution No. 41 of the year 2017, and in reference to Circular No. (17) 2022 Use of the NHRA-MVC Traceability Hub for Pharmaceutical Product Traceability, all pharmaceuticals entering the Kingdom of Bahrain are subject to serialization in accordance with the National Health Regulatory Authority (NHRA) Medicines Barcoding and Serialization Guideline; Kingdom of Bahrain; May 2019 Version 1.2.

As part of the Traceability initiative, a GS1 provided GLN number is required for all Agents/Distributors (Importers) in the Kingdom of who are involved in the following activities:

- Making transactions inside of the DUR and/or OFOQ system relating to imports of pharmaceutical products
- Receiving transactional data from the MAH in the form of EPCIS events

A GLN can be purchased from any authorized GS1 distributor anywhere in the world in some as low as \$30 as a one-off fee.

The NHRA, through our contracted partner MVC, are able to provide rebates up to this value for all Agents/Distributors (Importers) in the Kingdom of Bahrain who are involved in the above listed activities.

For general enquiries and support, please contact the NHRA-MVC Support Team at [NHRA-MVC-support@rfxcel.com](mailto:NHRA-MVC-support@rfxcel.com) or through our webpage [Contact Us – NHRA-MVC](#) for further information on this subject.

**Dr. Mariam Athbi Al-Jalahma**  
**Chief Executive Officer**